IBAT inhibitors have potential to boost life quality for patients
Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new treatments such as Livmarli (maralixibat)…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Liver donor type may sway primary sclerosing cholangitis outcomes
Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…
New app designed to be health record, journal for patients
Know Rare, a support platform for people living with rare diseases such as Alagille syndrome, launched a health journaling app to help patients…
Bemnifosbuvir-ruzasvir combo clears HCV for most in Phase 2 trial
A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to sustained clearance of the…
Poor sleep patterns evident in people with MASLD, MASH: Study
Troubled sleep is more common in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, than in age-matched adults…
Telehealth program helps improve hepatitis C treatment in rural US
A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would start treatment — and ultimately…
PBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union (EU), with an earlier decision…
Linerixibat eases ‘relentless’ PBC itching in Phase 3 trial, meeting goal
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…
Semaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
Phase 3 trials of treatment combo for hepatitis D expected in 2025
On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…